HOOK

Hookipa Pharma Inc
CAPPED RATING

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

Hookipa Pharma Inc (HOOK) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.7 / 5.0
Growth
D
Factor Score 1.3 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 0.5
Rev Growth YoY -94.5%
Gross Margin N/M
Price Return 3M 0.0%
Price Return 12M 0.9%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 1.5
ROE -105.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) D (1.3) C+ (2.7) C (2.4) C- (1.9) C (2.2)
2026-08-04 C+ (2.7) D (1.3) C+ (2.7) C (2.4) C- (1.9) C (2.2)
2026-08-03 C+ (2.7) C- (2.0) C+ (2.6) C (2.4) C- (2.0) C (2.4)
2026-08-02 C+ (2.7) C- (2.0) C+ (2.6) C (2.4) C- (1.9) C (2.3)